Skip to main navigation
TCR² Therapeutics
  • Our Science
  • Our Pipeline
  • Patients
    • Clinical Trials
    • Expanded Access Program
  • About Us
  • Investors & Media
    • Overview
    • Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • Analyst Coverage
    • Events
    • SEC Filings
    • FAQs
  • Get in Touch
  • Join Us
  • Home
  • Our Science
  • Our Pipeline
  • Patients
    ►
      ◄ Back
    • Clinical Trials
    • Expanded Access Program
  • About Us
  • Investors & Media
    ►
      ◄ Back
    • Overview
    • Press Releases
    • Events
    • Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • FAQs
  • Get in Touch
  • Join Us

Investors & Media

Press Releases

All News | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |

Jan 05, 2023

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 05, 2023

TCR² Therapeutics Announces Pipeline Priorities for 2023

Tools

  • Print Page
  • RSS Feeds
  • Email Alerts
  • Contact IR
  • Our Science
  • Our Pipeline
  • Patients
  • About Us
  • Investors & Media
  • Get in Touch
  • Join Us

© 2023 TCR² Therapeutics. All rights reserved.

TCR² Therapeutics